By Connor Hart
Medtronic received approval for its OmniaSecure defibrillation lead for placement within the right ventricle, from the Food and Drug Administration.
The medical technology company said Friday that the device, with a 1.6 millimeter diameter, is the smallest defibrillation lead. It was indicated for patients ages 12 and up, including those with smaller anatomies.
The lead connects to an implantable defibrillator, or a device that applies an electric charge or current to the heart, to restore a normal heartbeat.
Medtronic said its OmniaSecure device can be used to treat potentially life-threatening conditions including ventricular tachyarrhythmias, a heart rhythm disorder where the heart's lower chambers beat too fast, and ventricular fibrillation, an arrhythmia in which the heart's ventricles quiver instead of contracting normally.
While the device was approved for use within the right ventricle, the company is studying placing the device in the left bundle branch area. This placement, which still requires FDA approval, has the potential to enable physiologic pacing to more closely mimic the heart's natural conduction system, it said.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
April 25, 2025 18:12 ET (22:12 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。